XML 66 R55.htm IDEA: XBRL DOCUMENT v3.26.3
SCHEDULE OF SEGMENT REVENUE (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Revenues $ 2,242 $ 2,523 $ 7,411 $ 5,830
Cost of Revenues:        
Material and Labor 1,725 1,391 5,047 3,554
Other cost of revenues 277 268 1,126 807
Inventory write-off 1,085
Total Cost of Revenues 2,002 1,659 7,258 4,361
Research and development (R&D)        
Share based compensation     4,326 9,484
Total Research and development 3,273 3,635 12,331 11,528
Selling and marketing (S&M)        
Total Selling and marketing 2,394 4,392 12,795 11,314
General and administrative (G&A)        
Total General and administrative 3,452 5,888 12,329 16,157
Restructuring and other 1,074 1,074
Financial Income (expenses), net; 191 343 601 505
Segment net loss (9,762) (12,708) (37,775) (37,025)
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense        
Research and development (R&D)        
Payroll and Benefits 1,185 1,707 4,148 5,015
Share based compensation 801 2,351 3,267 6,051
General and administrative (G&A)        
Other G&A 1,466 1,830 4,914 5,091
Location, Statement of Income, Balance [Axis]: us-gaap:SellingAndMarketingExpense        
Research and development (R&D)        
Payroll and Benefits 2,618 2,975 10,411 7,732
Share based compensation (649) 567 475 1,379
Selling and marketing (S&M)        
Other S&M 425 850 1,909 2,203
Research and Development [Member]        
Research and development (R&D)        
Payroll and Benefits 1,178 1,089 4,059 3,063
Share based compensation (204) 576 406 1,889
Clinical trials 1,224 1,105 3,663 3,401
Other R&D $ 1,075 $ 865 $ 4,203 $ 3,175